The Wegovy pill after injections: what the OCTANE study shows
Patients who switched from injections to the Wegovy pill kept losing weight. What the study actually shows, and what it means for you.

A study presented on September 30, 2026 at the European Association for the Study of Diabetes (EASD) meeting in Milan caught the attention of the international press: patients who switched from weight-loss injections to the Wegovy pill (oral semaglutide 25 mg) kept losing weight. The headlines sounded spectacular. The data are more nuanced, and what has been approved in Europe matters too.
In short: in the OCTANE study, 194 US patients who switched from injections (Wegovy or tirzepatide) to the Wegovy pill lost, on average, a further 4.1% (4 kg) in 3 months. However, the study is retrospective, small, has no comparison group and was funded by the manufacturer. It does not show that the pill is "better" than injections. The Wegovy pill has been approved in the European Union since July 2026, and availability varies by country.
What the OCTANE study showed
The study analyzed data from 194 adults with obesity or overweight, patients of a US telehealth platform. All had previously been treated with injections (semaglutide, i.e. Wegovy, or tirzepatide) and switched to the Wegovy 25 mg pill, taken once a day.
Results after 3 months on the pill:
| Measure | Result |
|---|---|
| Average weight loss | −4.0 kg, i.e. −4.1% |
| Lost at least 5% | 40.7% of patients |
| Patients with BMI over 30 (obesity) | from 87.1% to 65.5% |
| Reported at least one improvement (clothes fit, eating habits, etc.) | 82.4% |
A few important details:
- average weight when switching to the pill was 100.5 kg, and average BMI was 34.5;
- an average of 36.8 days passed between the last injection and the first pill;
- only patients who continued treatment for at least 3 months, with no gaps longer than 30 days, were included.
What the headline "lose more weight" means
Reuters' headline was that patients switching to the pill "lose more weight". This means they kept losing weight after switching to the pill. It does not mean they lost more than they would have if they had stayed on injections, because the study did not have a group that stayed on injections.
Novo Nordisk's chief scientific officer said that "many patients do even better on the pill than on injections". The OCTANE data, however, do not allow such a comparison.
The study's limitations
The authors themselves list them, and they matter for interpretation:
- Retrospective: existing data were analyzed, rather than following a plan set in advance. A study like this cannot prove cause and effect.
- No control group: we don't know what would have happened to these patients if they had stayed on injections or stopped treatment.
- Selection: only those who continued the pill for 3 months were included. Those who quit (for example, because of side effects) do not appear in the results.
- Self-reported data for some of the measures.
- Small and short: 194 patients, 3 months.
- Funded by the manufacturer: the analysis is a collaboration between the telehealth platform and Novo Nordisk.
- We don't know the injection dose patients started from, or how much they had lost before.
The correct conclusion: switching to the pill appears to allow continued weight loss in patients who tolerate it, but controlled trials are needed to confirm it.
What we know from controlled trials: OASIS 4
For the efficacy of the pill itself, we have a rigorous trial. OASIS 4 (New England Journal of Medicine, 2025) compared oral semaglutide 25 mg with placebo in 307 adults without diabetes for 64 weeks, alongside diet and physical activity:
- 25 mg pill: −13.6% on average;
- placebo: −2.2%.
The manufacturer often cites a figure of about 17%. That refers only to patients who took the treatment as planned. The −13.6% figure includes all participants, whether or not they stopped treatment, and is the one reported as the primary result in the published trial.
For comparison, the Wegovy 2.4 mg injection led to −14.9% in the STEP 1 trial. Comparisons across different trials should be made with caution, though. See also how Mounjaro and Wegovy compare.
The Wegovy pill in Europe
- EU approval: the European Commission approved the Wegovy pill (oral semaglutide 25 mg, once a day) on July 15, 2026, for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) and at least one weight-related complication, alongside diet and physical activity.
- Availability: the manufacturer announced launches in several countries in the second half of 2026. The pill is already available in the US and the UK. Launch dates and prices differ from country to country, so check with your doctor and pharmacy.
- Not the same as Rybelsus: don't confuse the Wegovy pill with Rybelsus (oral semaglutide for type 2 diabetes, at lower doses).
How oral semaglutide is taken
Unlike the injections, the pill has strict rules for how it is taken, because it is poorly absorbed. For oral semaglutide, the package leaflet usually says the pill should be taken:
- on an empty stomach;
- with a little water (no more than half a glass);
- at least 30 minutes before your first meal, drink or other oral medicines.
Following these rules directly affects how much medicine reaches your bloodstream. You'll find the exact instructions for the Wegovy pill in the package leaflet, and you should discuss them with your doctor.
Is it worth switching from injections to the pill?
It can be a good option for people who:
- are afraid of needles or have trouble with injections;
- prefer a daily pill to a weekly injection;
- can follow the administration rules every morning.
The switch is made only with your doctor. They decide the starting dose and how fast to increase it, and if you had side effects on injections, they will take them into account (see GLP-1 side effects). Don't switch from one form to another on your own, and don't combine injections with pills.
If you're interested in the right long-term dose, also read the guide to the minimum effective dose and what trials show about lowering the dose after weight loss.
If you switch from injections to a pill, a GLP-1 tracker app such as Reko (partner app, iPhone) keeps both phases of your treatment, and your weight, in one record.
Conclusion
The OCTANE study suggests that patients who switch from injections to the Wegovy pill can keep losing weight, but it is a small, retrospective study with no comparison group. Headlines saying the pill is "better" than injections go further than the data. The truly important news for Europe is the July 2026 approval: the pill becomes a real option, while availability and price in each country remain to be seen.
Frequently asked questions
Is the Wegovy pill more effective than injections? That has not been shown. The OCTANE study did not compare the two directly. In separate controlled trials, the 25 mg pill led to −13.6% (OASIS 4) and the 2.4 mg injection to −14.9% (STEP 1).
How much weight did patients lose after switching to the pill? On average 4.0 kg (4.1%) in 3 months, and 40.7% lost at least 5%. However, the data come from a retrospective study with no control group.
Is the Wegovy pill approved in Europe? Yes. The Wegovy pill has been approved in the European Union since July 15, 2026. Launch dates and prices vary by country.
Can I switch from injections to the pill on my own? No. The switch is made only with your doctor, who decides the dose and how fast to increase it.
How is the pill taken? Usually on an empty stomach, with a little water, at least 30 minutes before food, drinks or other medicines. Follow the instructions in the package leaflet and those from your doctor.
Read also
- The future of GLP-1: pills and the next generation of medicines
- Mounjaro vs Wegovy: differences, results and how to choose
Useful calculators
- Wegovy calculator: the dose schedule for the injection and eligibility based on BMI.
- Ozempic calculator: the dose schedule in type 2 diabetes.
- BMI calculator: check whether you meet the eligibility criteria.
Sources
- Novo Nordisk. People switching from weight-loss injections to Novo's Wegovy pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 (press release, September 30, 2026).
- Reuters. Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study (September 30, 2026).
- Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393:1077-1087. doi:10.1056/NEJMoa2500969
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183
- Novo Nordisk. European Commission approval of the Wegovy pill (July 15, 2026).
Educational content, updated October 2026. It does not replace medical advice. Do not change the form or dose of your treatment without the agreement of the doctor who prescribed it.
This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.


